Incannex -IHL-675A Phase 1 clinical trial to assess safety and pharmacokinetics as a potential anti-inflammatory drug candidate

IHL-675A is a cannabinoid combination drug n animal models of:
comprising hydroxychloroquine sulphate (‘HCQ’)
and cannabidiol (‘CBD’).
HCQ is a disease-modifying anti-rheumatic
drug (DMARD) that works by calming a person’s
immune system.
CBD is a non-psychoactive phytocannabinoid
derived from the cannabis plant, associated
with anti-inflammatory and analgesic activity.